We describe a case of pneumonitis in a patient receiving selective intra-arterial chemotherapy for locally advanced breast cancer.
Despite the introduction of breast screening, 15 O of patients with breast cancer still present with locally advanced disease. The five-year survival of patients treated by local therapy alone is only 20%, and in an attempt to address this problem systemic treatment is now routinely offered to these patients.
Studies show that although overall survival is not significantly increased by the addition of chemotherapy, the time to first progression is significantly delayed by systemic therapy. This is due almost entirely to the time to locoregional progression rather than time to distant metastases. ' Since the activity of most drugs is dosedependent, regional chemotherapy which aims to deliver a high dose of drug directly to the tumour-bearing organ may be even more effective for this group of patients. As well as increasing the local concentration of drug, theoretically less drug will enter the systemic circulation and there will be less systemic toxicity.2 Nevertheless, depending upon how much drug is extracted or metabolised during first pass through the target organ, systemic toxicity may still occur.
Case report
A previously fit 40-year-old woman presented with histologically proven locally advanced inflammatory breast carcinoma. Staging revealed no evidence of axillary lymph nodes or systemic disease. Using our previously described technique,3 platinum occlusion coils were angiographically placed in the distal internal mammary artery. Following this, regional intra-arterial chemotherapy with mitomycin (7 mg/m'), mitozantrone (7 mg/M2n) and methotrexate (30mg/mi) was administered over four hours via the internal mammary artery. Four doses were administered at monthly intervals. A complete clinical response of her breast carcinoma was observed. Systemic toxicity was minimal and her lungs appeared normal (figure 1). However, three days following her last dose of chemotherapy she developed rapidly worsening dyspnoea and cough necessitating hospital admission.
Her condition rapidly worsened over four days with progressive respiratory failure. Chest radiography and computed tomography (CT) showed bilateral hilar enlargement with increased interstitial markings throughout each lung and patchy alveolar infiltrates (figure 2). Bilateral pleural effusions were also present. Transbronchial lung biopsy showed only nonspecific inflammatory changes and bronchialveolar lavage results were non-specific with no evidence of active lung infection. A diagnosis of drug-related pneumonitis was made and the patient was commenced on high-dose intravenous methylprednisolone. She made a rapid and full recovery.
Two months later she underwent mastectomy and axillary dissection. There was no pathological evidence of residual carcinoma in the breast and a solitary deposit was found in the axillary fat. No metastases were found in the lymph nodes.
Discussion
Pneumonitis is a well-recognised side-effect of many drugs, including the cytotoxics methotrexate and mitomycin (box 1). Pleural and mediastinal reactions may also occur. The condition is relatively rare, unpredictable and usually of insidious onset. It may occur up to 
